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Abstract The role of Vav in the transcriptional regulation of
the human interferon-Q (IFN-Q) promoter was investigated.
Overexpression of Vav in Jurkat-TAg cells enhanced T cell
receptor (TCR)-induced activation of a luciferase (Luc) reporter
gene construct driven by cis-regulatory element of the IFN-Q
gene (3346 to +7). Electrophoresis mobility shift and Luc
reporter assays demonstrated that the DNA-binding and
transcriptional activity of the proximal AP-1-dependent NFAT
site (positions 3172 to 3138), the AP-1/Ying-Yang 1 (YY1)-
binding site (3209 to 3184), and a consensus AP-1-binding site
were upregulated by Vav. Vav enhanced TCR-induced activa-
tion of c-Jun N-terminal kinase (JNK) and its upstream
regulator, Rho family GTPases. Finally, coexpression of a
dominant-negative Rac1 mutant suppressed Vav-mediated
upregulation of the transcriptional and DNA-binding activity
of the proximal NFAT/AP-1 site and the AP-1/YY1 site, as
well as the complete IFN-Q promoter activity. Vav activates the
IFN-Q promoter via upregulation of AP-1-binding through a
Rac1/JNK pathway. ß 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
The proto-oncogene product, Vav, expressed speci¢cally in
hematopoietic and trophoblast cells, has crucial roles in the
activation of T cells triggered through the T cell receptor
(TCR) [1,2]. Accumulating evidence suggests that Vav, which
is rapidly phosphorylated on tyrosine residues in response to
TCR stimulation, displays several T cell functions. Overex-
pression of Vav in T cells enhances basal and TCR-activated
transcription of the IL-2 [3^6] or IL-4 [7] genes. Analysis of
gene-disrupted mice indicated that T cell development is im-
paired in the absence of Vav and that Vav-de¢cient T cells
proliferate poorly and produce little IL-2 in response to stim-
ulation through the TCR [8^11]. The enhancement of IL-2
gene transcription by Vav is largely mediated by the activa-
tion of the distal NFAT element in the IL-2 gene promoter
[3^5,12].
The NFAT family contains ¢ve members, NFAT 1^5
[13,14]. NFAT 1^4 are capable of binding to the distal
NFAT-binding sequence in the IL-2 promoter, and activating
transcription driven from the NFAT sites when they are over-
expressed. The NFAT complex is composed of a cytoplasmic
subunit whose activity is controlled by subcellular localiza-
tion. In quiescent T cells, NFAT activity resides in the cyto-
plasm and, upon activation through the TCR, it translocates
into the nucleus [15] in a Ca2/calcineurin-dependent, and
cyclosporin A-sensitive manner [16,17]. In the nucleus,
NFAT associates with AP-1, an inducible nuclear component
[18^21].
The AP-1 complex is a dimer of members of the Jun, Fos
and activation transcription factor (ATF) families [22]. Each
of these proteins contains a leucine zipper, which permits its
dimerization with other members of the Jun/Fos/ATF family
and an adjacent basic region that mediates DNA-binding [22].
Among Jun family proteins, c-Jun is speci¢cally phosphory-
lated by c-Jun N-terminal kinase (JNK) at two positive regu-
latory sites residing within its amino-terminal activation do-
main [23,24]. Activation of JNK by Vav has been
demonstrated in non-T cells [25^27]. In addition, Vav displays
in vitro guanine nucleotide exchange factor (GEF) activity
toward Rho family GTPases, Rac and Cdc42 [2], which are
upstream signaling molecules in the pathway leading to JNK
activation [28,29]. These ¢ndings suggest that Vav may acti-
vate AP-1 and thereby contribute to upregulation of NFAT
activity. Consistent with this notion, we recently found that
transient overexpression of Vav greatly increases AP-1 activity
in T cells [6,30], although another recent study reported that
Vav does not play a role in AP-1 activation [31].
The ability of Vav to activate NFAT/AP-1 in the IL-2 pro-
moter [3^5,30], and the presence of a combined NFAT/AP-1-
binding site in the promoters of other cytokine genes
[13,21,32,33], including the interferon-Q (IFN-Q) gene [13,33^
36], suggest that Vav could regulate the expression of a num-
ber of cytokine genes having NFAT/AP-1-binding sites in
their cis-regulatory elements. However, the e¡ects of Vav on
cytokines other than IL-2 and IL-4 have not been analyzed.
Therefore, we have evaluated the role of Vav in IFN-Q gene
transcription. Here we report that Vav activates the IFN-Q
gene promoter, map some of the responsive elements and
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examine the mechanism through which Vav activates this pro-
moter.
2. Materials and methods
2.1. Antibodies and reagents
Mouse monoclonal antibodies (mAbs) against Vav or Rac1 were
obtained from Upstate Biotechnology (Lake Placid, NY, USA). Anti-
CD3 (OKT3) and anti-c-Myc (9E10) mAbs were puri¢ed from culture
supernatants of the corresponding hybridomas by protein G-Sephar-
ose chromatography. For TCR/CD3 cross-linking, a secondary anti-
mouse IgG antibody (Organon Teknica Corp., Durham, NC, USA)
was used. The anti-Cdc42 antibody was obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The anti-hemagglutinin (anti-
HA; clone 12CA5) mAb was obtained from Boehringer Mannheim
Biochemicals (Indianapolis, IN, USA). Horseradish peroxidase-conju-
gated F(abP)2 fragments of donkey anti-rabbit IgG or sheep anti-
mouse IgG were from Amersham (Piscataway, NJ, USA). All other
reagents were obtained from Sigma (St. Louis, MO, USA).
2.2. Plasmids
The cDNAs encoding c-Myc epitope-tagged Vav in the pEF mam-
malian expression vector [5], HA-JNK1, dominant-negative Rac1
(N17Rac1), or a luciferase (Luc) gene driven by three repeats of the
AP-1 site (TGACTCA) in the human metallothionein IIA gene were
described [30]. The Luc reporter genes driven by the human IFN-Q
promoter (3346 to +7; IFN-Q-Luc), three tandem repeats of the
3172/3138 site (3172/3138-Luc) or four repeats of the 3209/3184
site (3209/3184-Luc) were cloned in pGL3 basic vector (Promega,
Madison, WI, USA). As a control for transfection e⁄ciencies, a
L-galactosidase (L-gal) expression plasmid in the pEF vector was
used. The correct sequence of all constructs was veri¢ed by sequenc-
ing.
2.3. Cell culture, transfection and stimulation
Simian virus 40 T antigen-transfected human leukemic Jurkat T
(Jurkat-TAg) cells were grown in RPMI 1640 medium (Life Technol-
ogies, Inc., Gaithersburg, MD, USA) supplemented with 10% fetal
bovine serum (Harlan, Indianapolis, IN, USA), 2 mM L-glutamine,
1 mM sodium pyruvate, 10 mM HEPES, 1UMEM non-essential
amino acid solution and 100 U/ml each penicillin G and streptomycin.
Cells in logarithmic growth phase were transfected with various
amounts of plasmid DNAs by electroporation as described previously
[5,30]. In each experiment, cells in di¡erent groups were transfected
with the same total amount of plasmid DNA by supplementing ex-
pression vector DNA with the proper amounts of the corresponding
empty vector. On average, 35% of the cells expressed the transfected
plasmids as determined by FACS analysis of green £uorescence pro-
tein-cotransfected cells (data not shown). After 24 h, cells were resus-
pended (2^4U107/ml) in RPMI 1640 medium, equilibrated at 37‡C
for 5 min and either left unstimulated or stimulated with OKT3 (0.01^
1 Wg/ml), which had been cross-linked with a secondary anti-mouse
IgG antibody (1 Wg/ml). This antibody was added 1 min after the
addition of OKT3. The secondary antibody alone did not have any
e¡ect on the cells (data not shown).
2.4. Reporter assays
After 8 h of stimulation, cells were harvested, washed twice with
phosphate-bu¡ered saline, and lysed. Luc or L-gal activities in cell
extracts were determined as described previously [5,30]. Luc activity
was determined in triplicate by luminometry, and L-gal activity was
measured by spectrophotometry (400 nm). Luc activity was expressed
as arbitrary units normalized to L-gal activity in the same cells. The
standard deviation for triplicates was 6 10%, and each experiment
was repeated at least four times.
2.5. Electrophoresis mobility shift assay (EMSA)
Crude nuclear and cytoplasmic extracts were prepared as described
[30]. EMSA was performed as described [30,37] using oligonucleotides
corresponding to the 3172/3138 and 3209/3184 sites of the human
IFN-Q gene [36] or AP-1 [30].
2.6. Rac1 or Cdc42 activity
After stimulation for various times, cell lysates were prepared by
adding 2UNonidet P-40 (NP-40) lysis bu¡er (2% NP-40, 40 mM Tris^
HCl, pH 7.5, 300 mM NaCl, 10 mM EDTA, 10 mM sodium ortho-
phosphate, 4 mM Na3VO4, 20 Wg/ml each of aprotinin and leupeptin).
Cells were lysed for 10 min at 4‡C and insoluble materials were re-
moved by centrifugation (16 500Ug) at 4‡C for 10 min. Half of each
lysate was mixed with 2 Wg of glutathione S-transferase (GST) fusion
protein expressing the Rac1- or Cdc42-binding domain of mouse p21-
activated kinase 3 (GST^PBD; [38] for 1 h, followed by the addition
of 40 Wl of glutathione-coupled Sepharose 4B beads (Pharmacia Bio-
tech Inc., Piscataway, NJ, USA) for an additional 1 h at 4‡C. The
beads were washed four times with 1UNP-40 lysis bu¡er, boiled in 20
Wl 2ULaemmli’s bu¡er, subjected to SDS^12% polyacrylamide gel
electrophoresis (PAGE) analysis, and electrotransferred to polyvinyli-
dene di£uoride membranes (Millipore, Bedford, MA, USA). Mem-
branes were immunoblotted with anti-Rac1 or anti-Cdc42 antibodies
(1 Wg/ml), followed by horseradish peroxidase-conjugated secondary
antibodies [30]. The membranes were washed and visualized with an
enhanced chemiluminescence detection system (Amersham).
2.7. JNK assay
JNK1 was immunoprecipitated from cell lysates using an anti-HA
mAb, subjected to an in vitro kinase reaction GST^c-Jun as a sub-
strate, and kinase activity was determined as described [30]. Following
autoradiography to determine kinase activity, the membranes were
immunoblotted with an anti-c-Jun mAb as a loading control.
3. Results
3.1. Vav activates the IFN-Q promoter
The transcriptional activity of the IL-2 gene promoter is
upregulated by Vav [3^6,12]. However, it has not been known
whether Vav also activates the IFN-Q gene. Therefore, we ¢rst
investigated the e¡ect of Vav on human IFN-Q gene transcrip-
tion. As shown in Fig. 1, the transcriptional activity of Luc
reporter gene plasmid driven by the synthetic IFN-Q promoter
(IFN-Q-Luc) was stimulated in a dose-dependent manner by
OKT3 stimulation in empty vector-transfected cells. Overex-
Fig. 1. E¡ect of Vav on transcriptional activity of the IFN-Q pro-
moter. Cells were cotransfected with an IFN-Q-Luc reporter plasmid
(5 Wg) plus empty vector, c-Myc-tagged Vav, or Vav plus N17Rac1
(5 Wg each). After 24 h, cells were either left unstimulated or stimu-
lated for 8 h with OKT3, which has been linked using an anti-
mouse IgG antibody, then lysed for a Luc assay. The data shown
are representative of at least four experiments. Samples of the same
lysates were analyzed for the expression of Vav and N17Rac1 by
immunoblotting with anti-Vav and anti-c-Myc mAbs. Molecular
weight standards are shown (U103).
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pression of Vav further enhanced the activity of this reporter
gene.
Vav displays guanine nucleotide exchange factor activity
toward Rho family GTPases in vitro [2] and this activity is
associated with induction of downstream signaling events
leading to activation of the IL-2 gene promoter [6,12,39].
Therefore, we next evaluated the role of Rac1 on the activa-
tion of IFN-Q promoter by Vav, using dominant-negative
Rac1 mutant (N17Rac1). The Vav-mediated increase in the
transcriptional activity of IFN-Q-Luc was completely blocked
by a coexpressed N17Rac1 (Fig. 1), even though Vav was
properly overexpressed, suggesting that Vav activates the
IFN-Q gene promoter through a Rac1-dependent pathway.
3.2. E¡ect of Vav on DNA-binding and transcriptional
activities of AP-1-binding elements in the IFN-Q promoter
We have recently reported that Vav-induced upregulation
of the IL-2 gene transcription is mainly mediated by the en-
hancement of AP-1 binding to the distal NFAT/AP-1 site in
the IL-2 gene promoter [30]. However, it is not clear whether
the e¡ect of Vav on transcription of IFN-Q, as well as IL-2, is
the result of an increase in DNA^protein binding to the cog-
Fig. 2. E¡ect of Vav on DNA-binding and transcriptional activity of IFN-Q promoter elements and AP-1. A: Cells were transfected with empty
vector, Vav, or Vav plus N17Rac1. After 24 h, cells were either left unstimulated or stimulated by cross-linked OKT3 for 2 h. Nuclear extracts
were prepared and analyzed by EMSA, using 32P-labeled 3172/3138, 3209/3184 and AP-1 probes. The membrane was subjected to autora-
diography (top three panels), and total cellular extracts from the same transfection groups were immunoblotted with anti-Vav or anti-c-Myc
mAbs as indicated. These results are representative of at least four separate experiments. Arrows indicate speci¢c binding complexes. Molecular
weight standard are shown (U103). B^D: Cells were cotransfected with 3172/3138-Luc (B), 3209/3184-Luc (C) or AP-1-Luc (D) reporter
plasmids plus pEF, Vav, or a combination of Vav and N17Rac1. After 24 h, cells were either left unstimulated or stimulated for 8 h by cross-
linked OKT3. Luc activity was determined as in Fig. 1. The data shown are representative of at least four experiments. Proper expression of
Vav and N17Rac1 in the cell lysates was con¢rmed by immunoblotting with anti-Vav and anti-c-Myc mAbs (data not shown).
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nate sequence. Therefore, we next evaluated the e¡ect of Vav
on the binding and transcriptional activity for several cis-reg-
ulatory elements in the IFN-Q promoter, including the com-
bined NFAT/AP-1-binding site (3172/3138), and the AP-1/
YY1-binding site (3209/3184) [35,36], by comparison with a
consensus AP-1-binding site [30]. DNA-binding and transcrip-
tional activities were determined by an EMSA and Luc re-
porter assay, respectively. Anti-CD3 stimulation increased the
binding activity of 3172/3138 and 3209/3184, as well as AP-
1, in empty vector-transfected control cells (Fig. 2A). The
binding activity of all three elements was upregulated by over-
expression of Vav. These results correlated with the transcrip-
tional activity of the same elements. Thus, the transcriptional
activity of all the elements (3172/3138, 3209/3184 and AP-
1) was stimulated by OKT3 stimulation in empty vector-trans-
fected cells (Fig. 2B^D), and further enhanced by Vav coex-
pression. The Vav-mediated increase in the binding and tran-
scriptional activity of 3172/3138 and 3209/3184 was
blocked by a coexpressed N17Rac1 mutant (Fig. 2A^C),
even though Vav was properly overexpressed (data not
shown), suggesting that Vav activates 3172/3138 and
3209/3184 through a Rac1-dependent pathway. Consistent
with our recent report [30], N17Rac1 also abrogated the
Vav-mediated increase in the binding and transcriptional ac-
tivity of a consensus AP-1 site (Fig. 2A,D). We found that
Vav also enhanced the TCR-stimulated DNA-binding and
transcriptional activities of two other AP-1 sites (data not
shown).
3.3. Time course and dose dependence of Vav-mediated
activation of Rho family GTPases and JNK
Vav displays in vitro GEF activity for Rho family GTPases,
Rac1 and Cdc42 [2], and it also binds these two recombinant
GTPases in vitro [40]. Consistent with this GEF activity, Vav
has also been reported to activate JNK in non-hematopoietic
cells [25^27] and, more recently, also in TCR-stimulated T cells
[30]. Moreover, we demonstrated that Vav binds Rac1 and
Cdc42 in intact T cells [30]. To gain further insight into the
role of the Rac1/JNK pathway in Vav-induced activation of
the IFN-Q promoter, we next determined the e¡ect of Vav on
Rho family GTPase and JNK activities. The activated, GTP-
bound forms of Rac1 or Cdc42 in T cell lysates were captured
in vitro by a GST^PBD fusion protein and detected by im-
munoblotting [30,38]. OKT3 stimulation induced activation of
Rac1 and Cdc42 in Vav-transfected cells, reaching a maxi-
mum 10^20 min after stimulation (Fig. 3A). This OKT3-in-
duced activation was observed even in empty vector-trans-
fected cells (Fig. 3B). Overexpression of Vav upregulated
Rac1/Cdc42 activity in a dose-dependent manner in both un-
stimulated and OKT3-stimulated T cells (Fig. 3B).
JNK activity was determined in parallel by an in vitro ki-
nase assay using recombinant GST^c-Jun as substrate. Fig.
3A shows that in Vav-transfected cells, OKT3 stimulation
induced JNK activation, which reached a maximum after 20
min. The extent of JNK activity in both unstimulated and
OKT3-stimulated T cells was dependent on the dose of trans-
fected Vav protein (Fig. 3B).
Fig. 3. E¡ect of Vav on Rho family GTPases and JNK activity. Cells were transfected with 5 Wg each of HA-JNK1 plus Vav (5 Wg each; A)
or increasing amounts of Vav (1, 5 or 10 Wg; B) or empty vector (B). After 24 h, cells were either left unstimulated or stimulated by cross-
linked OKT3. Cell lysates were prepared at the indicated time points (A) or after 20 min of stimulation (B). Activated Rac1 or Cdc42 in cell
lysates were detected by precipitation with GST^PBD and immunoblotting with speci¢c mAbs (top two panels). JNK1 was immunoprecipitated
with an anti-HA mAb, and subjected to a radioactive in vitro kinase assay and SDS^PAGE. The membrane was subjected to autoradiography
(third panel from the top), followed by immunoblotting with an anti-c-Jun mAb as indicated (fourth panel from the top). Total cellular extracts
from the same transfection groups were immunoblotted with anti-Vav, anti-Rac1, anti-Cdc42 or anti-HA mAbs as indicated. The results shown
are representative of at least ¢ve separate experiments. Molecular weight standards are shown (U103).
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4. Discussion
IFN-Q is an important immunoregulatory cytokine respon-
sible for several activities in the immune system, including
induction of the Fc receptor, major histocompatibility com-
plex class I and II expression [41], regulation of cytokine genes
and activation of immune e¡ector cells [42]. IFN-Q production
is largely restricted to activated T cells and large granular
lymphocytes [42]. This cytokine belongs to a group of lym-
phokines whose synthesis parallels that of IL-2 and is inhib-
ited by cyclosporin A [13,33,42]. A wide variety of transcrip-
tion factors have been implicated in IFN-Q gene transcription
[42,43], and the corresponding promoter has several NFAT-
and/or AP-1-binding sites [34^36,43]. Since Vav stimulates IL-
2 gene transcription by upregulating the distal NFAT/AP-1-
binding site [3^5], this raised the unexplored possibility that
Vav may also regulate the IFN-Q gene.
Our present ¢ndings demonstrate that Vav activates the
IFN-Q gene promoter (Fig. 1). Analysis of distinct elements
within this promoter revealed that Vav induced Rac1-depen-
dent upregulation of the DNA-binding and transcriptional
activity of NFAT/AP-1 (3172/3138)- and AP-1/YY1 (3209/
3184)-binding sites, as well as a consensus AP-1 site (Fig. 2).
Vav also activated Rac1/Cdc42 and JNK (Fig. 3), suggesting
that Vav activates IFN-Q gene promoter through a Rac1/JNK/
AP-1 pathway. We reported recently that Vav overexpression
failed to exert a detectable e¡ect not only on the DNA-bind-
ing and transcriptional activities of the distal NFAT element
in the IFN-Q promoter at 3285/3257, but also on TCR-
stimulated Ca2 mobilization and nuclear translocation of
NFAT [30]. This promoter region in the human IFN-Q gene
contains a consensus NFAT-binding sequence at position
3280/3270, which is necessary for its inducible transcription-
al activation. The importance of this site in IFN-Q transcrip-
tion was demonstrated by mutational analysis, but DNase
footprinting or EMSA analysis indicated that this region
does not bind AP-1 [30,35,36]. In addition to NFAT, the
region of the IFN-Q promoter between nucleotides 3284 and
3260 was also found to bind nuclear factor UB (NF-UB) [35].
This suggests that NF-UB, which is positively regulated by
Vav [44], may be a target for Vav-mediated regulation at
this site, even though our earlier study failed to show activa-
tion of this site by Vav [30].
In contrast to the above distal NFAT site, the cis-element
at 3163/3155 is similar to composite NFAT/AP-1 elements
found in other cytokine gene promoters [13], and was found
to bind an NFAT/AP-1 complex [36]. The importance of this
site is evident from ¢ndings that point mutation in it de-
creased IFN-Q gene transcription and, conversely, NFAT
overexpression enhanced gene expression [36]. The e¡ects of
Vav on transcriptional and DNA-binding activities of the
3172/3138 were concordant (Fig. 2), suggesting that Vav
stimulates IFN-Q gene transcription by upregulating the
DNA-binding activity of the combined NFAT/AP-1-binding
site at 3172/3138 (Fig. 2A).
An additional AP-1-binding site in the human IFN-Q pro-
moter at positions 3209/3184 binds a complex of AP-1 and
Ying-Yang 1 (YY1; [36]). Two constitutive YY1-binding sites
have been identi¢ed in this region at positions Y1 (3203/
3199) and Y2 (3221/3217) [45,46], but the role of YY1 in
IFN-Q transcription is controversial [36,45,46]. The AP-1 site
at 3196/3183 contributes to mitogen- or IL-18-induced IFN-
Q transcription, and it also plays a positive role in IL-12-de-
pendent activation of the IFN-Q promoter in primary CD4
T cells [47,48]. Here we demonstrate that the DNA-binding
and transcriptional activities of the AP-1/YY1-binding site
(3284/3209) were also upregulated by Vav (Fig. 2A,C). How-
ever, it remains to be determined whether Vav a¡ects the
binding of AP-1 and/or YY1 to this site.
Taken together, our previous [30] and current ¢ndings dem-
onstrate that Vav overexpression enhances the DNA-binding
and transcriptional activities of reporter genes containing AP-
1-binding sites, i.e. 3172/3138 and 3284/3209 (as well as a
consensus AP-1 site), but has no detectable e¡ect on an AP-1-
independent NFAT site (3285/3257). These results suggest
that Vav does not directly a¡ect NFAT-binding but, rather,
acts primarily on AP-1. Nevertheless, others reported reduced
TCR-induced Ca2 mobilization in Vav-de¢cient T cells
[11,44,49,50], but the biological signi¢cance of this reduction
is unclear since NFAT2 nuclear translocation remained intact
in Vav-de¢cient T cells [50].
The TCR-induced activation of Rac1 and Cdc42 slightly
preceded JNK activation (Fig. 3A). This result and the
dose-dependent upregulation of Rac1/Cdc42 by Vav further
support a role for Vav in the JNK/AP-1 pathway. This is
consistent with ¢ndings using several other cell types [25^27]
and with our recent report [30]. However, the physiological
role of a Vav in JNK activation is not completely understood,
since Vav-de¢cient T cells display intact JNK activation
[49,50]. It is possible that a compensatory mechanism leading
to JNK activation (e.g. expression of other Vav family mem-
bers) might be upregulated in the chronic absence of Vav,
consistent with the results of a recent study [51]. In addition,
JNK activation is not required for TCR/CD28-costimulated
IL-2 production by primary T cells [52]. Nevertheless, Vav
could play a physiological role in JNK activation in memory
or e¡ector T cells.
In summary, our ¢ndings lend further support to the notion
that upregulation of AP-1 activity via the Rac1/JNK pathway
is the primary physiological mechanism through which Vav
activates various cytokine genes, including the IL-2 [3^6], IL-4
[7] and IFN-Q ([30] and herein) genes. Additional studies are
required in order to identify the intermediates and the relevant
interactions in this signaling pathway leading from Vav to
AP-1 activation.
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